pegaptanib sodium (Macugen)

DRUG5 trials

Sponsors

Eyetech Pharmaceuticals, Pfizer, Palmetto Retina Center, LLC

Conditions

Age-Related Macular DegenerationAge-Related Macular Degeneration (AMD)Branch Retinal Vein OcclusionDiabetic Macular EdemaMacular Degeneration

Phase 2

Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula

CompletedNCT00040313

Eyetech PharmaceuticalsDiabetic Macular Edema

Start: 2002-10-31End: 2005-02-28Updated: 2006-05-03

Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)

CompletedNCT00215670

Eyetech PharmaceuticalsAge-Related Macular Degeneration

Start: 2002-11-30End: 2006-05-31Target: 125Updated: 2006-05-03

Phase 4

Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions

CompletedNCT00324116

PfizerMacular Degeneration

Start: 2006-07-31End: 2008-08-31Updated: 2010-03-23

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

Eyetech PharmaceuticalsAge-Related Macular Degeneration (AMD)

Start: 2006-06-30Target: 1000Updated: 2007-01-15

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

CompletedNCT00406107

Palmetto Retina Center, LLCBranch Retinal Vein Occlusion

Start: 2006-01-31End: 2008-04-30Updated: 2014-09-12